A clinical registry for longitudinal data on the clinical, psychosocial, and economic impact of lung cancer treatment in Italy

Lung Cancer Observational Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN67197140

Enrollment

500

Registered

2022-10-11

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer Cancer

Interventions

Current interventions as of 05/04/2024: LUCENT is a web-based registry developed to facilitate data collection on several different outcomes of lung cancer patients diagnosed in the early stage in It

• Economic impact assessment of innovative technologies or treatment pathways (e.g., Do different surgical medical devices influence healthcare resource utilisations for a single episode of hospitalis

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age >18 years 2. Patients suffering from lung cancer candidates for surgical intervention 3. Signature of informed consent

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Data will be entered into the registry at the time of patient follow-up, which is done yearly: 1. EuroQol-5D 2. Current smoking habit 3. Presence or absence of co-morbidites 4. BMI (kg/m²) 5. Lung function: 5.1. Spirometry - FEV1%, FVC%, DLCO/VA% 5.2. 6 minute walking test 5.3. Lung scintigraphy 5.4. Cardiopulmonary exercise testing 6. Cancer staging - cTNM, pTNM 7. Other diagnostic tests: 7.1. Bronchoscopy 7.2. FNAB 7.3. Mediastinoscopy 7.4. EBUS 7.5. EUS 8. Treatment history (chemotherapy, radiotherapy, surgery) 9. Progression of disease	—

Measure

Time frame

Data will be entered into the registry at the time of patient follow-up, which is done yearly: 1. EuroQol-5D 2. Current smoking habit 3. Presence or absence of co-morbidites 4. BMI (kg/m²) 5. Lung function: 5.1. Spirometry - FEV1%, FVC%, DLCO/VA% 5.2. 6 minute walking test 5.3. Lung scintigraphy 5.4. Cardiopulmonary exercise testing 6. Cancer staging - cTNM, pTNM 7. Other diagnostic tests: 7.1. Bronchoscopy 7.2. FNAB 7.3. Mediastinoscopy 7.4. EBUS 7.5. EUS 8. Treatment history (chemotherapy, radiotherapy, surgery) 9. Progression of disease

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 5, 2026